Diagnostics Connect:
Central US 2026

Dr. David Peng

David Peng, Ph.D., earned his bachelor’s degree in Biochemistry from Nankai University and his Ph.D. in Molecular Biology from the University of Texas. He subsequently conducted postdoctoral research at the Genomics Institute of the Novartis Research Foundation. Before co-founding Genovo, Dr. Peng held senior scientific roles at Gen-Probe and Genoptix, a Novartis clinical laboratory, where he contributed to the research and development of advanced molecular diagnostic technologies.

Dr. Peng is Co-Founder and President of Genovo and Co-Founder and Chief Technology Officer of Dunwill Medical. He has extensive experience in developing molecular and cellular diagnostic assays, instruments, and biomarker-based technologies. Throughout his career, he has led multidisciplinary teams in translating scientific discoveries into practical diagnostic solutions and has supported the regulatory approval and commercialization of multiple in vitro diagnostic products through the U.S. FDA and China’s NMPA.

Dr. Boehringer is the Co-Founder and Chief Scientific Officer of Artemis Dx, where he oversees the company's scientific direction, leads client-sponsored point-of-care development programs, and drives business development, including authoring grant proposals for government and NGO funding partners. He brings more than three decades of leadership in in vitro diagnostics (IVD) research and development, with deep expertise spanning assay development, product commercialization, regulatory strategy, and intellectual property analysis. Prior to co-founding Artemis Dx, he served as Senior Vice President of Research and Development at Biomerica Inc., where he directed the company's point-of-care assay development programs and secured more than $500,000 in contract development business. Earlier, as Vice President of Technology Development at Diagnostic Consulting Network, he managed custom assay development programs from design through regulatory submission and served as Principal Investigator on multiple NIH SBIR grants as well as funded programs from the Bill & Melinda Gates Foundation, FIND, BARDA, and DTRA. Dr. Boehringer's earlier career included senior R&D leadership roles at Genzyme Diagnostics, Quidel Corporation, and Pacific Biotech, where he built and led multidisciplinary teams that brought rapid diagnostic tests for infectious disease and women's health to market, including influenza, RSV, Strep A, PDG and hCG assays. His work has repeatedly taken products from feasibility through FDA clearance, in some cases in a matter of weeks. He has also participated in numerous due diligence and integration efforts supporting company acquisitions. Before entering industry, Dr. Boehringer held academic research positions at the Wistar Institute and as Assistant Professor at the University of Pennsylvania School of Dental Medicine, where his work focused on immunology and microbial pathogenesis. He has served as a Scientific Reviewer for NIH study sections continuously between 2019 and 2024. Dr. Boehringer holds a Ph.D. and M.S. in Biochemistry from the Swiss Federal Institute of Technology (ETH Zurich).

Donald Green

Donald Green is a thoughtful and results-driven business development manager with more than 15 years of experience in the diagnostics industry, including over six years at Cytiva. He brings strong expertise in diagnostics and assay development and is known for translating complex technical challenges into practical solutions. Donald is recognized for building trusted customer relationships through a collaborative approach, maintaining a strong focus on outcomes, and helping teams stay aligned on priorities that drive business impact.